Edition:
United States

G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

62.94USD
18 Sep 2018
Change (% chg)

-- (--)
Prev Close
$62.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
103,283
52-wk High
$69.23
52-wk Low
$18.45

Chart for

About

G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38... (more)

Overall

Beta: --
Market Cap(Mil.): $2,102.48
Shares Outstanding(Mil.): 33.40
Dividend: --
Yield (%): --

Financials

  GTHX.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -2.55 -- --
ROI: -49.19 1.52 12.66
ROE: -49.20 0.25 14.84

BRIEF-G1 Therapeutics Reports Qtrly Loss Per Share Of $0.70

* G1 THERAPEUTICS PROVIDES FIRST QUARTER 2018 CORPORATE AND FINANCIAL UPDATE

May 03 2018

Earnings vs. Estimates